Published in J Pharmacol Sci on August 05, 2006
Ultrasound-guided radial artery catheterization in infants and small children. Pediatr Crit Care Med (2013) 1.49
Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients. Anesthesiology (2009) 1.39
Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol (2010) 1.38
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol (2013) 1.14
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2011) 1.09
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol (2006) 1.07
Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic Clin Pharmacol Toxicol (2008) 1.03
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci (2012) 1.00
Ultrasound evidence of the optimal wrist position for radial artery cannulation. Can J Anaesth (2009) 0.95
Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy. Surg Endosc (2011) 0.94
Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol (2010) 0.93
Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol (2011) 0.91
A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem (2005) 0.87
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol (2014) 0.87
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun (2010) 0.87
Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci (2011) 0.86
Fluorescence navigation hepatectomy by visualization of localized cholestasis from bile duct tumor infiltration. J Am Coll Surg (2010) 0.84
Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells. Endocr Res (2012) 0.83
Peripheral sensitization caused by insulin-like growth factor 1 contributes to pain hypersensitivity after tissue injury. Pain (2011) 0.83
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res (2006) 0.83
Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther (2013) 0.82
A novel method for ultrasound-guided radial arterial catheterization in pediatric patients. Anesth Analg (2014) 0.82
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism (2009) 0.82
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem (2012) 0.82
Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res (2008) 0.81
Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion. Neuropeptides (2010) 0.81
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun (2010) 0.81
Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun (2010) 0.80
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist. Vascul Pharmacol (2005) 0.80
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res (2005) 0.79
The RACHS-1 risk category can be a predictor of perioperative recovery in Asian pediatric cardiac surgery patients. J Anesth (2013) 0.79
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice. Eur J Pharmacol (2009) 0.79
Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep (2009) 0.78
Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. Life Sci (2012) 0.78
Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy. Vascul Pharmacol (2007) 0.78
Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol (2003) 0.77
YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett (2005) 0.77
Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543. Bioorg Med Chem (2013) 0.77
ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol (2008) 0.77
Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur J Pharmacol (2003) 0.77
Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. Eur J Pharmacol (2006) 0.77
Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells. Pharmacology (2006) 0.77
Effect of vasopressin on type IV collagen production in human mesangial cells. Regul Pept (2008) 0.76
Retracted Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther (2005) 0.76
Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses. J Pharmacol Exp Ther (2014) 0.75
Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor. J Physiol Sci (2011) 0.75
Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding. Intern Med (2017) 0.75
Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology (2009) 0.75
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. Clin Exp Pharmacol Physiol (2015) 0.75
[Selection of pediatric endotracheal tube size by ultrasonography]. Masui (2011) 0.75
Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol (2007) 0.75
Acute development of superior vena cava syndrome after pediatric cardiac surgery. Paediatr Anaesth (2008) 0.75
[A multicenter survey of pediatric endotracheal tube management]. Masui (2015) 0.75
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors. Biol Pharm Bull (2005) 0.75
Intraoperative monitoring of movement of an entrapped coronary guidewire by transesophageal echocardiography. Anesth Analg (2008) 0.75
YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction. Eur J Pharmacol (2006) 0.75
Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biol Pharm Bull (2002) 0.75
Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions. Clin Exp Pharmacol Physiol (2012) 0.75
Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn J Pharmacol (2002) 0.75
[Case report of TGA-1 neonate with hyponatremia]. Masui (2011) 0.75